Investors once again lined up behind Thrive Earlier Detection and its potentially revolutionary cancer diagnostic The one-year-old start raised a $257 million Series B round from a syndicate of venture and crossover investors, including round leaders Casdin Capital and Section 32 and new investors Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, […]
Exact Sciences Corp.
How Exact Sciences built a DNA screening test for colorectal cancer
In a seemingly endless war on cancer, the best weapon remains early detection, according to Graham Lidgard, senior vice president of R&D at Exact Sciences Corp. For Lidgard, and the rest of the team at the Madison, Wisc.-based molecular diagnostics maker, the battlefield is colorectal cancer, 1 of the most common, and deadliest, cancers in […]
Exact Sciences lands 1st joint approval through FDA-CMS parallel review
Wisconsin-based Exact Sciences (NSDQ:EXAS) won landmark approval for its Cologuard home colorectal cancer test, becoming the 1st company to successfully navigate a pilot program for parallel review by both FDA and Medicare regulators.
Press Release: FDA approves first non-invasive DNA screening test for colorectal cancer
The U.S. Food and Drug Administration today approved Cologuard, the first stool-based colorectal screening test that detects the presence of red blood cells and DNA mutations that may indicate the presence of certain kinds of abnormal growths that may be cancers such as colon cancer or precursors to cancer.
Insulet’s Q4 losses widen but 2010 losses fall 16 percent | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
Two accused in insider trading of molecular diagnostics stocks
The federal Securities & Exchange Commission charged a Baltimore business consultant and his uncle in Cleveland of an insider trading scheme that netted the pair more than $600,000.
Exact Sciences registers $150 million securities sale
Exact Sciences Corp. (NSDQ:EXAS) filed a shelf registration statement for the sale of up to $150 million in equity, debt and warrants, according to the federal Securities & Exchange Commission.
In a press release, the Madison, Wis.-based molecular diagnostics developer said it does not have immediate plans to offer the securites, but wants to keep its options open.
Exact Sciences has steady revenue, losses
Exact Sciences Corp.’s (NSDQ:EXAS) net losses for its 2010 second quarter were almost double the company’s revenues, but still less than during the same period last year.
The company reported a net loss of $2.5 million, or 6 cents per diluted share, on revenues of $1.3 million during the three months ended June 30. Those results compare with a net loss of $2.4 million, or 8 cents per diluted share, on sales of $1.3 million during Q2 2009.
Exact Sciences inks biomarkers deal with Belgian firm
Exact Sciences Corp. (NSDQ:EXAS) inked a licensing deal with Belgium-based OncoMethylome Sciences for that company’s DNA methylation biomarkers.
The Madison, Wis.-based company gained exclusive worldwide rights for up to two of OncoMethylome’s biomarkers utilized in its stool-based detection of colorectal cancer, the companies said.
Exact Sciences posts Q4 revenue gains, narrows losses
Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:
Quest Diagnostics launches blood test for colorectal cancer
Quest Diagnostics Inc. (NYSE:DGX) introduced a new blood test with the potential to identify colorectal cancer by detecting chemical changes in specific strands of genetic material.
Quest Diagnostics plans to market its new ColoVantage test as a supplement to other screening tools such as colonoscopy and fecal occult blood tests. Company officials said in prepared remarks that while ColoVantage has not yet been clinically validated, they hope the relative ease of a blood test would convince individuals who previously have passed on more invasive tests to be screened.
